Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

Immunicum AB. (12/29/17). "Press Release: Immunicum AB (publ) Announces the Outcome of the Rights Issue [Not for US, AU, CA, et al.]".

Organisations Organisation Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
  Organisation 2 Nasdaq Stockholm
  Group Nasdaq OMX (Group)
Products Product ilixadencel
  Product 2 investment banking
Index term Index term Immunicum–SEVERAL: investment, 201711–201712 capital increase SEK200m net SEK168m with 25m new shares at SEK8/share
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)
     


   
Record changed: 2018-10-20

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top